Assessments of clinical benefit
| Clinical benefit . | Responders n/N (%) . | Nonresponders n/N (%) . | All patients n/N (%) . |
|---|---|---|---|
| Resolution of B-CLL symptoms or fatigue | 17/17 (100) | 28/42 (67) | 45/59 (76) |
| Resolution of massive splenomegaly | 9/10 (90) | 7/19 (37) | 16/29 (55) |
| Improvement in WHO PS | 8/20 (40) | 9/49 (18) | 17/69 (25) |
| Improvement in anemia | 11/15 (73) | 14/36 (39) | 25/51 (49) |
| Clinical benefit . | Responders n/N (%) . | Nonresponders n/N (%) . | All patients n/N (%) . |
|---|---|---|---|
| Resolution of B-CLL symptoms or fatigue | 17/17 (100) | 28/42 (67) | 45/59 (76) |
| Resolution of massive splenomegaly | 9/10 (90) | 7/19 (37) | 16/29 (55) |
| Improvement in WHO PS | 8/20 (40) | 9/49 (18) | 17/69 (25) |
| Improvement in anemia | 11/15 (73) | 14/36 (39) | 25/51 (49) |